Evaluating treatment efficacy: potential biases behind randomized controlled trials.

David T. Felson, The verdict favors nonsteroidal antiinflammatory drugs for treatment of osteoarthritis and a plea for more evidence on other treatments. Arthritis & Rheumatism. ,vol. 44, pp. 1477- 1480 ,(2001) , 10.1002/1529-0131(200107)44:7<1477::AID-ART267>3.0.CO;2-O

David T. Felson, Yuqing Zhang, An update on the epidemiology of knee and hip osteoarthritis with a view to prevention Arthritis & Rheumatism. ,vol. 41, pp. 1343- 1355 ,(1998) , 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9

Bruce M. Psaty, Curt D. Furberg, Marco Pahor, Michael Alderman, Lewis H. Kuller, National guidelines, clinical trials, and quality of evidence. JAMA Internal Medicine. ,vol. 160, pp. 2577- 2580 ,(2000) , 10.1001/ARCHINTE.160.17.2577

David Moher, Alison Jones, Leah Lepage, for the CONSORT Group, Use of the CONSORT Statement and Quality of Reports of Randomized Trials: A Comparative Before-and-After Evaluation JAMA. ,vol. 285, pp. 1992- 1995 ,(2001) , 10.1001/JAMA.285.15.1992

Catherine L. Hill, Michael P. LaValley, David T. Felson, Secular changes in the quality of published randomized clinical trials in rheumatology Arthritis & Rheumatism. ,vol. 46, pp. 779- 784 ,(2002) , 10.1002/ART.512

Douglas G Altman, Kenneth F Schulz, David Moher, Matthias Egger, Frank Davidoff, Diana Elbourne, Peter C Gøtzsche, Thomas Lang, Consort Group, The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration Annals of Internal Medicine. ,vol. 134, pp. 663- 694 ,(2001) , 10.7326/0003-4819-134-8-200104170-00012